Celgene, Novartis File Suit Against Generic Ritalin

Law360, New York (February 28, 2007, 12:00 AM EST) -- Pharmaceutical companies Celgene Corp. and Novartis AG have filed a patent infringement suit against generics maker Abrika Pharmaceuticals Inc. over a time-release version of Ritalin, a drug used to treat attention deficit/hyperactive disorder.

Celgene revealed the suit in a filing with the U.S. Securities and Exchange Commission Tuesday. The complaint, which was filed in U.S. District Court in New Jersey and Delaware, was issued in response to Abrika’s Abbreviated New Drug Application registered with the U.S. Food and Drug Administration last year.

Abrika is seeking approval...
To view the full article, register now.